ReviewCurrent hematologic malignancy reports2018
Updates in the Pathology of Precursor Lymphoid Neoplasms in the Revised Fourth Edition of the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues.
Review in Current hematologic malignancy reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 52 citations in OpenAlex.
- Sequential dual-targeting biomimetic nanovesicles for bone marrow-specific delivery of bortezomib in multiple myeloma.Frontiers in bioengineering and biotechnology · 2025Article
- Proteasome and PARP1 dual-target inhibitor for multiple myeloma: Fluzoparib.Biochemistry and biophysics reports · 2024Article
- Inserting EF1α-driven CD7-specific CAR at CD7 locus reduces fratricide and enhances tumor rejection.Leukemia · 2023Article
- CCR9 overexpression promotes T-ALL progression by enhancing cholesterol biosynthesis.Frontiers in pharmacology · 2023Article
- Targeting DNA Methylation in Leukemia, Myelodysplastic Syndrome, and Lymphoma: A Potential Diagnostic, Prognostic, and Therapeutic Tool.International journal of molecular sciences · 2022Review
- Endocan in Acute Leukemia: Current Knowledge and Future Perspectives.Biomolecules · 2022Review
- Prognostic Significance of Comprehensive Gene Mutations and Clinical Characteristics in Adult T-Cell Acute Lymphoblastic Leukemia Based on Next-Generation Sequencing.Frontiers in oncology · 2022Article
- Mature B cell acute lymphoblastic leukaemia with KMT2A-MLLT3 transcripts in children: three case reports and literature reviews.Orphanet journal of rare diseases · 2021Review
- Diagnostic Utility of SOX4 Expression in Adult T-Cell Leukemia/Lymphoma.Diagnostics (Basel, Switzerland) · 2021Article
- [The pathological diagnosis and differential diagnosis of hematopoietic cell tumors of ambiguous lineage].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2021Article
- Facts and Challenges in Immunotherapy for T-Cell Acute Lymphoblastic Leukemia.International journal of molecular sciences · 2020Review
- Novel Therapies in the Treatment of Adult Acute Lymphoblastic Leukemia.Current hematologic malignancy reports · 2020Review
- A Pilot Study of Circulating Monocyte Subsets in Patients Treated with Stem Cell Transplantation for High-Risk Hematological Malignancies.Medicina (Kaunas, Lithuania) · 2020Article
- Gene expression ofOncology letters · 2019Article
- MLPA as a complementary tool for diagnosis of chromosome 21 aberrations in childhood BCP-ALL.Journal of applied genetics · 2019Article
- Rapid Identification of Key Copy Number Alterations in B- and T-Cell Acute Lymphoblastic Leukemia by Digital Multiplex Ligation-Dependent Probe Amplification.Frontiers in oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewAcute lymphoblastic leukemias (ALL) are malignant disorders of immature B or T cells that occur characteristically in children, usually under the age of 6 (75%). Approximately 6000 new cases of ALL are diagnosed each year in the USA, 80-85% of which represent B-ALL forms. Most presentations of B-ALL are leukemic, whereas T-ALL presents with a mediastinal mass, with or without leukemic involvement. The revised fourth edition of the World Health Organization (WHO) classification (2017) has introduced some changes in both B and T-ALL. Here, we summarize the categories of lymphoblastic leukemia/lymphomas as defined by the WHO and recent developments in the understanding of this group of hematologic malignancy. RECENT
findingsTwo provisional categories of B-ALL have now been identified including B-ALL, BCR-ABL1-like, and B-ALL with iAMP21. The Philadelphia chromosome-like B-ALL includes forms of the disease that shares the expression profiling of B-ALL with t(9;22) but lack such rearrangement. The second one shows amplification of part of the chromosome 21. Both entities are associated with worse prognosis. Within the T-ALL group, an early precursor T cell form has now been introduced as a provisional category. Such group demonstrates expression of stem cell and myeloid markers in conjunction with the T cell antigens. The current review summarizes the recent updates to the WHO classification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.